This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Biohaven Ltd. Securities Class Action
Business securities lawsuit

Biohaven Ltd. Securities Class Action

Analysis based on 8 articles · First reported Jul 25, 2025 · Last updated Sep 03, 2025

Sentiment
-50
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is impacted by the potential financial liabilities Biohaven Pharmaceutical Holding Company faces due to the class action lawsuit, which could lead to significant monetary damages. The stock price of Biohaven Pharmaceutical Holding Company has already experienced a substantial decline following the United States — Food and Drug Administration's decision regarding its drug application, indicating negative investor sentiment.

Pharmaceuticals Legal Services
Event Summary

Faruqi & Faruqi is investigating Biohaven Pharmaceutical Holding Company and encouraging investors to join a federal securities class action lawsuit. The lawsuit alleges that Biohaven Pharmaceutical Holding Company and its executives made false and misleading statements regarding the regulatory prospects of troriluzole for spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder. This follows an announcement on May 14, 2025, by Biohaven Pharmaceutical Holding Company that the United States — Food and Drug Administration extended the PDUFA date for troriluzole by three months and plans an advisory committee meeting. This news caused Biohaven Pharmaceutical Holding Company's stock price to fall by 19.53% on May 15, 2025. Investors who suffered losses between March 24, 2023, and May 14, 2025, are encouraged to seek the role of lead plaintiff by the September 12, 2025, deadline.

Entities Involved
stock
Biohaven Pharmaceutical Holding Company
Biohaven Pharmaceutical Holding Company is facing a federal securities class action lawsuit for allegedly making false and misleading statements regarding its drug candidates, troriluzole and BHV-7000. Its stock price fell significantly after the FDA extended the PDUFA date for troriluzole.
Importance 100.0 Sentiment -70.0
priv
Faruqi & Faruqi
Faruqi & Faruqi is a national securities law firm that is investigating potential claims against Biohaven Pharmaceutical Holding Company and encouraging investors to join a class action lawsuit.
Importance 80.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration extended the PDUFA date for Biohaven Pharmaceutical Holding Company's troriluzole new drug application and is planning an advisory committee meeting, which led to a significant drop in Biohaven Pharmaceutical Holding Company's stock price.
Importance 70.0 Sentiment 0.0
per
James Wilson
James Wilson is a Securities Litigation Partner at Faruqi & Faruqi who is encouraging investors to contact him regarding the Biohaven Pharmaceutical Holding Company class action lawsuit.
Importance 60.0 Sentiment 0.0
Relationships
Faruqi & Faruqi related ↔ United States — Food and Drug Administration
Faruqi & Faruqi related ↔ James Wilson
United States — Food and Drug Administration related ↔ James Wilson
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.